API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/01/2891814/0/en/Y-mAbs-Announces-New-Interim-Analysis-of-Phase-2-Data-for-Naxitamab-at-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/07/2877228/0/en/Y-mAbs-Reports-First-Quarter-2024-Financial-Results-and-Recent-Corporate-Developments.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171
https://www.globenewswire.com/news-release/2023/05/23/2674387/0/en/Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-High-Risk-Neuroblastoma-approved-in-Brazil.html
https://www.globenewswire.com/news-release/2023/05/08/2663801/0/en/Y-mAbs-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments-and-Updates-2023-Financial-Guidance.html
https://www.globenewswire.com/news-release/2023/02/02/2600538/0/en/Y-mAbs-and-the-European-Medicines-Agency-Reach-Agreement-on-the-Pediatric-Investigation-Plan-for-Naxitamab.html
https://www.globenewswire.com//news-release/2022/12/21/2577938/0/en/Y-mAbs-Announces-Partnership-Regarding-Early-Access-Program-for-DANYELZA-naxitamab-gqgk-in-Europe.html
https://www.globenewswire.com//news-release/2022/12/08/2570344/0/en/Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-High-Risk-Neuroblastoma-Approved-in-China.html
https://www.globenewswire.com/news-release/2022/09/26/2522618/0/en/Y-mAbs-Announces-Regulatory-Filing-for-DANYELZA-naxitamab-gqgk-in-Brazil.html
https://www.globenewswire.com/news-release/2022/05/26/2451583/0/en/Y-mAbs-Announces-Naxitamab-Chemoimmunotherapy-Investigational-Trial-for-High-Risk-Neuroblastoma-Meets-Primary-Endpoint.html
https://www.globenewswire.com/news-release/2021/09/10/2295176/0/en/Y-mAbs-to-Host-Key-Opinion-Leader-Webinar-on-DANYELZA-naxitamab-gqgk-Frontline-and-HITS-Data-in-High-Risk-Neuroblastoma.html
https://endpts.com/with-pipeline-setbacks-mounting-united-snares-priority-voucher-for-inhaled-formulation-of-pah-med-tyvaso/
https://www.globenewswire.com/news-release/2020/12/18/2147881/0/en/Y-mAbs-Signs-Distribution-Agreement-with-Swixx-for-DANYELZA-naxitamab-gqgk-and-Omburtamab-in-Eastern-Europe.html
https://www.globenewswire.com/news-release/2020/12/18/2147881/0/en/Y-mAbs-Signs-Distribution-Agreement-with-Swixx-for-DANYELZA-naxitamab-gqgk-and-Omburtamab-in-Eastern-Europe.html
https://www.streetinsider.com/Corporate+News/Y-mAbs+Therapeutics+%28YMAB%29%2C+Takeda+%28TAK%29+Announce+Exclusive+License+and+Distribution+Agreement+for+DANYELZA%C2%AE+%28naxitamab-gqgk%29+and+Omburtamab+in+Israel/17683384.html
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow
https://www.targetedonc.com/view/fda-approves-naxitamab-for-treatment-of-relapsed-refractory-high-risk-neuroblastoma
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171
https://www.globenewswire.com/news-release/2020/10/16/2109854/0/en/Y-mAbs-Announces-Update-on-Naxitamab-and-Omburtamab-in-Neuroblastoma.html
https://www.globenewswire.com/news-release/2020/06/02/2042283/0/en/Y-mAbs-Announces-U-S-FDA-Acceptance-of-Biologics-License-Application-for-Danyelza-naxitamab-for-the-Treatment-of-Neuroblastoma-for-Priority-Review.html
https://seekingalpha.com/news/3509713-y-mabs-naxitamab-shows-positive-effect-neuroblastoma-study
https://www.fiercebiotech.com/biotech/y-mabs-ramps-up-headcount-post-ipo-hiring-spree